Effects of retinal morphology on contrast sensitivity and reading ability in neovascular age-related macular degeneration

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 11, 2010, Pages 5431-5437

  Keane, Pearse A ^a   Patel, Praveen J ^b   Ouyang, Yanling ^a   Chen, Fred K ^b   Ikeji, Felicia ^b   Walsh, Alexander C ^a   Tufail, Adnan ^b   Sadda, Srinivas R ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; COMPUTER PROGRAM; CONTRAST SENSITIVITY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROSENSORY RETINA THICKNESS; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; READING; RETINA; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINAL THICKNESS; SUBRETINAL FLUID VOLUME; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; CHOROIDAL NEOVASCULARIZATION; CONTRAST SENSITIVITY; CROSS-SECTIONAL STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; READING; RETINA; SUBRETINAL FLUID; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 79955022849     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4846     Document Type: Article

References (27)

1. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.
2. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355: 1419-1431.
3. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006;26:383-390.
4. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566-583.
5. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148:43-58.e1.
6. Keane PA, Chang KT, Liakopoulos S, Jivrajka RV, Walsh AC, Sadda SR. Effect of ranibizumab retreatment frequency on neurosensory retinal volume in neovascular AMD. Retina. 2009;29:592-600.
7. Keane PA, Mand PS, Liakopoulos S, Walsh AC, Sadda SR. Accuracy of retinal thickness measurements obtained with cirrus optical coherence tomography. Br J Ophthalmol. 2009;93:1461-1467.
8. Keane PA, Liakopoulos S, Jivrajka RV, et al. Evaluation of optical coherence tomography retinal thickness parameters for use in clinical trials for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009;50:3378-3385.
9. Keane PA, Liakopoulos S, Chang KT, et al. Relationship between optical coherence tomography retinal parameters and visual acuity in neovascular age-related macular degeneration. Ophthalmology. 2008;115:2206-2214.
10. Moutray T, Alarbi M, Mahon G, Stevenson M, Chakravarthy U. Relationships between clinical measures of visual function, fluorescein angiographic and optical coherence tomography features in patients with subfoveal choroidal neovascularisation. Br J Ophthalmol. 2008;92:361-364.
11. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med. 2008;358:2606-2617.
12. Keane PA, Liakopoulos S, Ongchin SC, et al. Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49:3115-3120.
13. Hogg RE, Chakravarthy U. Visual function and dysfunction in early and late age-related maculopathy. Prog Retin Eye Res. 2006;25: 249-276.
14. Ergun E, Maár N, Radner W, Barbazetto I, Schmidt-Erfurth U, Stur M. Scotoma size and reading speed in patients with subfoveal occult choroidal neovascularization in age-related macular degeneration. Ophthalmology. 2003;110:65-69.
15. Patel PJ, Chen FK, Rubin GS, Tufail A. Intersession repeatability of contrast sensitivity scores in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009;50:2621-2625.
16. Csaky KG, Richman EA, Ferris FL. Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci. 2008;49:479-489.
17. Duivenvoorden R, de Groot E, Stroes ES, Kastelein JJ. Surrogate markers in clinical trials: challenges and opportunities. Atherosclerosis. 2009;206:8-16.
18. Lloyd R, Harris J, Wadhwa S, Chambers W. Food and Drug Administration approval process for ophthalmic drugs in the US. Curr Opin Ophthalmol. 2008;19:190-194.
19. Hazel CA, Petre KL, Armstrong RA, Benson MT, Frost NA. Visual function and subjective quality of life compared in subjects with acquired macular disease. Invest Ophthalmol Vis Sci. 2000;41: 1309-1315.
20. Sadda SR, Joeres S, Wu Z, et al. Error correction and quantitative subanalysis of optical coherence tomography data using computerassisted grading. Invest Ophthalmol Vis Sci. 2007;48:839-848.
21. Patel PJ, Bunce C, Tufail A, ABC Trial Investigators OB. A randomised, double-masked phase III/IV study of the efficacy and safety of Avastin(R) (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age-related macular degeneration: clinical trial design. Trials. 2008;9:56.
22. Mansfield J, Ahn S, Legge G, Leubeker A. A new reading acuity chart for normal and low vision. In: Ophthalmic Visual Optics: Non-Invasive Assessment of the Visual System. OSA Technical Digest. Vol 3. Washington, DC: Optical Society of America; 1993: 232-235.
23. Joeres S, Tsong JW, Updike PG, et al. Reproducibility of quantitative optical coherence tomography subanalysis in neovascular agerelated macular degeneration. Invest Ophthalmol Vis Sci. 2007; 48:4300-4307.
24. Grossniklaus HE, Green WR. Choroidal neovascularization. Am J Ophthalmol. 2004;137:496-503.
25. Keane PA, Liakopoulos S, Chang KT, et al. Comparison of the optical coherence tomographic features of choroidal neovascular membranes in pathological myopia versus age-related macular degeneration, using quantitative subanalysis. Br J Ophthalmol. 2008;92:1081-1085.
26. Hayashi H, Yamashiro K, Tsujikawa A, Ota M, Otani A, Yoshimura N. Association between foveal photoreceptor integrity and visual outcome in neovascular age-related macular degeneration. Am J Ophthalmol. 2009;148:83-89.e1.
27. Sayanagi K, Sharma S, Kaiser PK. Photoreceptor status after antivascular endothelial growth factor therapy in exudative age-related macular degeneration. Br J Ophthalmol. 2009;93:622-626.